Publicaciones (468) Publicaciones de ANDRES MANUEL R CERVANTES RUIPEREZ

2024

  1. Divarasib plus cetuximab in KRAS G12C-positive colorectal cancer: a phase 1b trial

    Nature Medicine, Vol. 30, Núm. 1, pp. 271-278

  2. European clinical practice guidelines for the definition, diagnosis, and treatment of oligometastatic esophagogastric cancer (OMEC-4)

    European Journal of Cancer, Vol. 204

  3. Generation, Expansion, and Biobanking of Gastrointestinal Patient-Derived Organoids from Tumor and Normal Tissues

    Methods in molecular biology (Clifton, N.J.), Vol. 2777, pp. 123-133

  4. Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with gastric cancer

    ESMO Open, Vol. 9, Núm. 2

  5. Pharmacokinetics (PK) of Tiragolumab in First-in-Human Study in Patients with Mixed Solid Tumors (GO30103)

    Journal of Clinical Pharmacology, Vol. 64, Núm. 5, pp. 544-554

  6. Regorafenib in patients with metastatic colorectal cancer in Spain: from clinical trials to real-world evidence

    Future Oncology

  7. The role of anti-EGFR rechallenge in metastatic colorectal cancer, from available data to future developments: A systematic review

    Cancer Treatment Reviews, Vol. 124

  8. Updated treatment recommendation for third-line treatment in advanced colorectal cancer from the ESMO Metastatic Colorectal Cancer Living Guideline

    Annals of oncology : official journal of the European Society for Medical Oncology

  9. ctDNA whole exome sequencing in pancreatic ductal adenocarcinoma unveils organ-dependent metastatic mechanisms and identifies actionable alterations in fast progressing patients

    Translational Research, Vol. 271, pp. 105-115

2023

  1. "Proteotranscriptomic analysis of advanced colorectal cancer patient derived organoids for drug sensitivity prediction"

    Journal of experimental & clinical cancer research : CR, Vol. 42, Núm. 1, pp. 8

  2. Anti-TIGIT Antibody Tiragolumab Alone or With Atezolizumab in Patients With Advanced Solid Tumors: A Phase 1a/1b Nonrandomized Controlled Trial

    JAMA oncology

  3. Definition, diagnosis and treatment of oligometastatic oesophagogastric cancer: A Delphi consensus study in Europe

    European Journal of Cancer, Vol. 185, pp. 28-39

  4. Efficacy and safety of maintenance therapy with pamiparib versus placebo for advanced gastric cancer responding to first-line platinum-based chemotherapy: Phase 2 study results

    Cancer Medicine, Vol. 12, Núm. 12, pp. 13145-13154

  5. Erdafitinib in patients with advanced solid tumours with FGFR alterations (RAGNAR): an international, single-arm, phase 2 study

    The Lancet Oncology, Vol. 24, Núm. 8, pp. 925-935

  6. European expert panel consensus on the clinical management of BRAFV600E-mutant metastatic colorectal cancer

    Cancer Treatment Reviews, Vol. 115

  7. FOLFOXIRI plus bevacizumab as standard of care for first-line treatment in patients with advanced colon cancer

    ESMO Open

  8. How organoids can improve personalized treatment in patients with gastro-esophageal tumors

    Current Opinion in Pharmacology, Vol. 69

  9. In the Literature: January 2023

    ESMO Open

  10. In the Literature: March 2023

    ESMO Open

  11. In the literature: July 2023

    ESMO Open